Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00799396 · ClinicalTrials.gov registry record · Phase 4
Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 682
- Enrollment target
NCT00799396: Completed Phase 4 study, sponsored by University of Maryland, Baltimore.
NCT00799396 is a Phase 4 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 682 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (32% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00799396, a Phase 4 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 682 participants
- Enrollment target
Study Summary
One of the most common ways for preventing coronary heart disease (CHD) is to take aspirin or clopidogrel. However, studies have shown that not all people respond to these medications. The variance in treatment response may be linked to genetics. This study will examine the effects of aspirin and clopidogrel in a population whose genes are well known in order to determine the role that genes play in treatment responses.
Primary Outcome
Baseline minus post clopidogrel/pre-aspirin platelet rich plasma (PRP) maximum aggregation.
Interventions
- DRUG Aspirin
- DRUG Clopidogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 682 participants |
| Start Date | 2006-07 |
| Est. Completion | 2012-02 |
| Phase | Phase 4 |
What the finished NCT00799396 record still lists
NCT00799396 is an interventional study that assigns participants to a tested intervention. The registered 682 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (32% higher).
The record links to 0 conditions, and to 2 interventions - of which Aspirin is the first listed.
NCT00799396 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00799396 about?
NCT00799396 is a clinical study titled "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)". One of the most common ways for preventing coronary heart disease (CHD) is to take aspirin or clopidogrel. However, studies have shown that not all people respond to these medications. The variance in treatment response may be linked to genetics. This study will examine the effects of aspirin and cl...
What is the current status of trial NCT00799396?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 682 participants. The study started on 2006-07. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00799396?
The interventions under investigation include: Aspirin (DRUG), Clopidogrel (DRUG).
Who is sponsoring clinical trial NCT00799396?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00799396's enrollment target sits among peer trials
682 119th of 2000 higher than 1,882 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05382559 · 681 participants · Phase 1
A Study of ASP3082 in Adults With Advanced Solid Tumors
- NCT06795087 · 684 participants
Discharge Medication Use Post-Operatively in GU Cancer Patients
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia